L1.11 Kilder

Antivirale midler

http://depts.washington.edu/nwaetc/presentations/uploads/261/croi_2017_highlightswhats_new_in_antiretrovirals_part_2.pdf

European AIDS Clinical Society

Desinfeksjonsmidler

Walker JT (Ed). Decontamiantion in hospitals and healthcare. Woodhead Publishing Ltd, Cambridge 2014.

Fraise A, Maillard J-Y, Sattar SA (Eds) Russel, Hugo & Ayliffe’s Principles and Practice of Disinfection, Preservation and Sterilization, 5th edition. Wiley-Blackwell, Chichester Uk 2013.

McDonnell GE. Antisepsis, Disinfection and Sterilisation. Types, Action and Resistance. ASM Press, Washington DC 2007.

Block SS. Disinfection, Sterilisation and Preservation. Lippincott Williams & Wilkins, Philadelphia 2001

Spaulding EH. Chemical disinfection of medical and surgical materials. In: Lawrence C and Block SS (Eds). Disinfection, Sterilization and Preservation, 4th edn. Philadelphia: Lea & Febiger, p. 517-31.

Won SY, Wong ES. Surgical site infections. I.Mayhall CG. (red.) Hospital Epidemiology and Infection Control, 4e. Lippincott Williams & Wilkins, Philadelphia 2012.

Mangram AJ et al. Guideline for prevention of surgical site infection, 1999. Am J Infect Control 1999;27:97-134.

WHO Guidelines on Hand Hygiene in Health Care, World Health Organization 2009

Tanner J, Swarbrook S, Stuart J. Cochrane Database Syst Rev 2008;(1):CD004288.

Pottinger J, Burns S, Manske C. Am J Infect Control 1989;17:340-344.

Moolenaar RL, Crutcher JM, San Joaquin VH, et al. Infect Control Hosp Epidemiol 2002;21:80-85.

Waring L, Armstron R, Bolding F, et al. J Infect Dis 1997;175(4):992-995.

Widmer A.F. et al. J Hosp Infect (2010);74:112-122.

Norsk Standard NS-EN 12791, Kjemiske desinfeksjonsmidler og anticeptika. Kirurgiske hånddesinfeksjonsmidler. Prøvingsmetode og krav (fase 2/trinn 2)

Immunglobuliner

Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.

Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.

Aukrust P, Frøland SS, Liabakk N-B, Müller F, Nordøy I, Haug C, Espevik T. Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-43.

Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)-beyond immunodeficiencies and neurolgy. Clin Exp Immunol 2009;158 Suppl 1:23-33.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200:1068-77.

Cunningham-Rundles C. How I treat common variable immune deficiency. Blood. 2010;116:7-15.

Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther. 2011;11:1455-67.

Remdesivir

N Engl J Med . 2020 Jul 17;NEJMoa2021436. doi: 10.1056/NEJMoa2021436. Online ahead of print. Dexamethasone in Hospitalized Patients with Covid-19

WHO: Descriptive analysis of COVID-19-related spontaneous related spontaneous reports from VigiBase: interim results. 2020-08-26. https://www.who.int/medicines/regulation/medicines-safety/COVID19-PV-update6.pdf?ua=1

Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. WHO Solidarity trial consortium. https://doi.org/10.1101/2020.10.15.20209817

Remdesivir for the Treatment of Covid-19 — Final Report, NEJM. DOI: 10.1056/NEJMoa2007764

Rifapentin

Dorman SE et al; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400

FDA: Full prescribing information, Rifapentine

WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment

UpToDate : Rifapentine: Drug information

FHI: Forskrivning av ukesdosering med rifapentine og isoniazid